NEW YORK (GenomeWeb) – RPRD Diagnostics announced today that it has signed an agreement to help Children's Minnesota develop a pharmacogenomic testing process.

Under the terms of the deal, Children's Minnesota will begin using RPRD's pharmacogenomic testing platform within its cancer and blood disorder clinic and its neurology/psychology practice. The partners will work together to implement the service. Additional terms were not disclosed.